USP's Work to Help Build Supply Chain Resilience

Expanding the Supply of Quality Medicines

A resilient supply chain withstands acute disruptions so that safe, effective, and quality medicines can be supplied to patients around the globe, in adequate quantities, when they are needed. USP standards and solutions are critical tools supporting global medicines supply chain resilience, enabling consistency and uniformity in the production of safe, quality medicines from raw materials through packaging, distribution and delivery, building trust in medicines.

<table>
<thead>
<tr>
<th>Information and Innovation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine Supply Map: Identifies, characterizes, and quantifies risk in the upstream supply chain, developing insights from over 250 million data points from more than 40 sources.</td>
</tr>
<tr>
<td>Advanced Manufacturing Technologies (AMT) Workforce Development: Training in applications to help upskill staff to implement AMT.</td>
</tr>
<tr>
<td>USP Pharmaceutical Continuous Manufacturing (PCM) Knowledge Center: Captures and shares PCM knowledge across six domains of knowledge from R&amp;D through manufacturing and regulatory affairs.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Collaboration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulatory Capability Building: USAID-funded PQM+ program works in low- and middle-income countries building capabilities to help ensure the supply of quality medicines in their countries.</td>
</tr>
<tr>
<td>USP-APEC Center of Excellence: Convenes regulators from 21 economies from Pacific rim countries focused on supply chain quality. Sponsored by the U.S. FDA.</td>
</tr>
<tr>
<td>Advancing Preparedness: USP is an active participant in Biden Administration formal advisory committees for the HHS Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA).</td>
</tr>
<tr>
<td>Global Pandemic Prevention and Biodefense Center: USP participation in cross-sectoral initiative to develop Monoclonal antibodies (mAbs) for the world’s top 100 pathogens most likely to cause a future pandemic.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Policy Development and Advocacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congressional Engagement: Advocacy through comments and letters to Congress and Federal Agencies focused on upstream supply chain insights to reduce shortages, combat antimicrobial resistance (AMR), and reduce the barriers to adoption of pharmaceutical continuous manufacturing.</td>
</tr>
<tr>
<td>Public Policy White Papers: AMR, falsified and substandard vaccines, and supply chain resiliency were the focus of USP white papers to inform policy dialogues.</td>
</tr>
<tr>
<td>Joint Policy Recommendations: USP collaborated with the American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology to develop policy recommendations to improve the resiliency of the U.S. supply chain and mitigate medical supply shortages.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Initiatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicine Supply Map: Identifies, characterizes, and quantifies risk in the upstream supply chain, developing insights from over 250 million data points from more than 40 sources.</td>
</tr>
<tr>
<td>Advanced Manufacturing Technologies (AMT) Workforce Development: Training in applications to help upskill staff to implement AMT.</td>
</tr>
<tr>
<td>USP Pharmaceutical Continuous Manufacturing (PCM) Knowledge Center: Captures and shares PCM knowledge across six domains of knowledge from R&amp;D through manufacturing and regulatory affairs.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Essential Standards</th>
</tr>
</thead>
</table>

### Key Initiatives
- **Medicines Patent Pool (MPP):** collaborates with over 80 countries to ensure equitable access to essential medicines, acting as a repository for global medicine patents.
- **Good Manufacturing Practices (GMP):** ensures the quality of medicines, processes, equipment, facilities, and personnel.
- **Good Laboratory Practices (GLP):** promotes integrity in research, including drug development.
- **Good Clinical Practice (GCP):** ensures the ethical conduct of clinical trials.
- **Globally Harmonized System of Classification and Labeling (GHS):** universal system for classifying physical, health, and environmental hazards of chemicals.

### Essential Standards
- **Standards for Raw Materials:** quality control for ingredients and excipients.
- **Standards for Chemicals:** purity and safety.
- **Standards for Packaging:** durability and tamper-evident.
- **Standards for Finished Products:** stability and performance.
- **Standards for Testing:** methods and protocols.

### Collaboration
- **Regulatory Capability Building:** USAID-funded PQM+ program works in low- and middle-income countries building capabilities to help ensure the supply of quality medicines in their countries. 
- **USP-APEC Center of Excellence:** convenes regulators from 21 economies from Pacific rim countries focused on supply chain quality. Sponsored by the U.S. FDA.
- **Advancing Preparedness:** USP is an active participant in Biden Administration formal advisory committees for the HHS Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA).
- **Global Pandemic Prevention and Biodefense Center:** USP participation in cross-sectoral initiative to develop Monoclonal antibodies (mAbs) for the world’s top 100 pathogens most likely to cause a future pandemic.

### Policy Development and Advocacy
- **Congressional Engagement:** Advocacy through comments and letters to Congress and Federal Agencies focused on upstream supply chain insights to reduce shortages, combat antimicrobial resistance (AMR), and reduce the barriers to adoption of pharmaceutical continuous manufacturing.
- **Public Policy White Papers:** AMR, falsified and substandard vaccines, and supply chain resiliency were the focus of USP white papers to inform policy dialogues.
- **Joint Policy Recommendations:** USP collaborated with the American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical Oncology to develop policy recommendations to improve the resiliency of the U.S. supply chain and mitigate medical supply shortages.

### Key Initiatives
- **Medicines Patent Pool (MPP):** collaborates with over 80 countries to ensure equitable access to essential medicines, acting as a repository for global medicine patents.
- **Good Manufacturing Practices (GMP):** ensures the quality of medicines, processes, equipment, facilities, and personnel.
- **Good Laboratory Practices (GLP):** promotes integrity in research, including drug development.
- **Good Clinical Practice (GCP):** ensures the ethical conduct of clinical trials.
- **Globally Harmonized System of Classification and Labeling (GHS):** universal system for classifying physical, health, and environmental hazards of chemicals.

### Essential Standards
- **Standards for Raw Materials:** quality control for ingredients and excipients.
- **Standards for Chemicals:** purity and safety.
- **Standards for Packaging:** durability and tamper-evident.
- **Standards for Finished Products:** stability and performance.
- **Standards for Testing:** methods and protocols.